Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galera Therapeutics filings document a clinical-stage oncology company’s material agreements, governance matters, capital structure and operating disclosures. The company’s SEC reports include 8-K events for asset transactions involving dismutase mimetics, amendments to preferred-stock terms, conversions of Series B Non-Voting Convertible Preferred Stock, pre-funded warrant exercises, and executive compensation arrangements.
Galera’s proxy and annual-meeting materials cover stockholder voting procedures, director nominations, governance requirements and related capital-structure disclosures. Its public-company records also identify GRTX common stock on the OTCQB Market and provide formal disclosure of financial results, reporting obligations, risk-related matters and corporate actions affecting the company’s oncology development business.
Galera Therapeutics, Inc. entered into a letter agreement with Joel Sussman, its Chief Accounting Officer, Treasurer, Secretary, and a named executive officer, establishing retention-based cash bonus payments tied to timely completion and filing of certain company reporting obligations.
Under the agreement, Mr. Sussman may receive up to $250,000 in total retention bonuses. Any retention bonuses paid will reduce, on a dollar-for-dollar basis, any severance otherwise due to him under his existing employment agreement. If his employment is involuntarily terminated without cause, or he resigns for good reason, any unpaid retention bonus will be paid regardless of whether the original conditions are met.
Galera Therapeutics, Inc. (GRTX) president and CEO J. Mel Sorensen, who is also a director, reported an open market sale of company stock. On 11/20/2025, he sold 70,000 shares of common stock at a weighted average price of $0.0201 per share, with individual trades executed between $0.02 and $0.0201. After this transaction, he beneficially owned 195,029 shares of Galera Therapeutics common stock in direct ownership.
GRTX has a Form 144 notice indicating that an affiliate plans to sell up to 70,000 shares of common stock through Raymond James & Associates on the OTC Markets, with an approximate sale date of 11/20/2025 and an aggregate market value of 1400.00. The table lists 75,462,390 shares of the issuer’s stock as outstanding, providing context for the planned sale size. The seller originally acquired 217,015 common shares on 03/06/2021 via a stock option exercise paid in cash. By signing the notice, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s current or prospective operations.
Galera Therapeutics (OTCQB:GRTX) reported a smaller quarterly loss and a strategic reset. For the quarter ended September 30, 2025, net loss was $1.4 million versus $5.6 million a year ago as operating expenses fell sharply; research and development was $0.1 million and general and administrative was $1.3 million.
Cash and cash equivalents were $4.5 million, with total assets of $5.0 million and a stockholders’ deficit of $149.2 million. A royalty purchase liability of $151.0 million remained on the balance sheet at quarter‑end, and was subsequently assigned to Biossil alongside the sale of the company’s dismutase mimetic assets for $3.5 million in October 2025. Management states that existing cash plus the $3.5 million will fund limited operations for at least twelve months from issuance.
The business has shifted to a pan‑NOS inhibitor program for difficult breast cancers. An investigator‑sponsored Phase 1/2 study at Houston Methodist is funded by an NIH grant, and a second TNBC trial is being planned with the I‑SPY 2 consortium, subject to additional capital. In December 2024, Galera acquired Nova Pharmaceuticals and issued 119,318 Series B non‑voting convertible preferred shares (each convertible into 1,000 common shares if approved), and completed a $2.9 million private placement at $0.065 per share or pre‑funded warrant. Common shares outstanding were 75,462,390 as of November 12, 2025.
Galera Therapeutics (GRTX) reported that Blackstone executed a notice of assignment acknowledging Galera’s assignment of the Amended and Restated Purchase and Sale Agreement to Biossil Inc. and agreeing to look solely to Biossil for all obligations of the “Seller” under that agreement.
This step follows Galera’s Asset Purchase and Sale Agreement under which it sold all of its dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711), to Biossil, with Biossil assuming liabilities related to those assets. The notice of assignment was executed after the transaction and is filed as Exhibit 10.1.
Galera Therapeutics (GRTX) agreed to sell its avasopasem (GC4419), rucosopasem (GC4711), and other dismutase mimetic assets to Biossil Inc. under an Asset Purchase and Sale Agreement, as amended.
The purchase price includes an upfront payment of $3,500,000 and potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105,000,000 in aggregate. Biossil also agreed to assume all further rights and obligations of Galera under the Amended and Restated Purchase and Sale Agreement dated November 14, 2018, with Clarus IV Galera Royalty AIV, L.P., which is affiliated with Blackstone Life Sciences.
The agreement includes customary representations, warranties, and covenants, with certain confidentiality, indemnification, and payment provisions surviving closing. Galera plans to file the full agreement as an exhibit to its next Form 10-Q.